Stereotactic Radiosurgery · Spine

Spine SBRT: Foundations & Patient Selection

The cord constraint, the decision frameworks, and the workflow that make ablative spine treatment safe

Spine stereotactic body radiotherapy delivers an ablative, conformal dose to a vertebral target sitting millimeters from the spinal cord. That single anatomical fact, the cord constraint, governs everything, and the decision to use SBRT is made within structured frameworks (NOMS, SINS, the ESCC grade) that integrate neurologic, oncologic, mechanical, and systemic factors with the surgeon and radiation oncologist at the same table. This page covers why and when spine SBRT is chosen and how the target and cord are defined; dose, fractionation, toxicity, and the postoperative setting are on the clinical practice page.

Timoteo Almeida, MD, MSc, PhD, FCNS | Departments of Neurological Surgery and Radiation Oncology

Orientation

Conventional palliative radiotherapy controls pain in many spinal metastases but achieves only modest durable local control, particularly for radioresistant histologies (renal cell, melanoma, sarcoma). Spine SBRT escalates the biologically effective dose to achieve high durable local control, valuable in oligometastatic disease and longer-prognosis patients, but only by exploiting a steep gradient against the cord. The decision is therefore never radiotherapeutic alone: it requires assessing neurologic compromise, mechanical stability, and the surgical question first, which is what the NOMS, SINS, and ESCC frameworks formalize.

Part I

Why Spine SBRT

1.Durable local control versus palliation

The rationale for spine SBRT is durable local control: ablative dose delivers local control on the order of 80–90% in modern series, with particular value for radioresistant histology, oligometastatic disease, and patients expected to live long enough for durability to matter. Current ASTRO guidance conditionally favors SBRT over conventional palliative RT only for selected patients with good performance status who do not require surgery and have no neurologic signs or symptoms. For pain specifically, the randomized evidence is nuanced and is developed on the clinical page: single-fraction SBRT did not beat conventional RT for pain in one trial, whereas a 2-fraction regimen did in another.

Part II

Decision Frameworks

2.NOMS, ESCC, and SINS

Three tools structure the decision and are used together:

NOMS (Neurologic, Oncologic, Mechanical, Systemic): the integrating framework. Neurologic = degree of epidural cord compression and myelopathy; Oncologic = tumor radiosensitivity; Mechanical = spinal stability; Systemic = disease burden and ability to tolerate treatment. The combination, not any single axis, dictates SBRT vs surgery vs conventional RT vs combined therapy.
ESCC (epidural spinal cord compression) grade: the Bilsky 6-point scale (0, 1a/1b/1c, 2, 3) describing how far tumor encroaches on the thecal sac and cord. High-grade ESCC (2–3) in a radioresistant tumor generally requires separation surgery to create a safe gap before SBRT, because the cord cannot tolerate the ablative dose needed at the tumor. When the histology is radiosensitive, conventional external beam radiotherapy can decompress the cord without an operation even at grade 2 or 3, which is why the neurologic and oncologic axes of NOMS have to be read together rather than in sequence.
SINS (Spinal Instability Neoplastic Score): grades mechanical instability (location, pain, alignment, lytic vs blastic, vertebral collapse, posterior-element involvement). A score indicating instability points to stabilization/surgery; SBRT does not restore mechanical stability and can worsen fracture risk.

The two questions SBRT cannot answer by itself Before treating a spinal metastasis with SBRT, settle two surgical questions first: (1) Is there high-grade epidural cord compression (ESCC 2–3)? If so, consider separation surgery to create a cord-to-tumor gap. (2) Is the spine mechanically unstable (SINS)? If so, it needs stabilization. SBRT controls tumor; it neither decompresses the cord acutely nor stabilizes the spine.

Part III

Workflow and Target Definition

3.Simulation, fusion, and contouring

Spine SBRT demands near-rigid immobilization (vacuum/body fixation), thin-slice planning CT, and high-quality MRI fusion to define both the tumor and the cord/thecal sac, since the entire plan is shaped around sub-millimeter cord avoidance. Target delineation follows consensus guidelines (the International Spine Radiosurgery Consortium recommendations for target volume definition): the CTV deliberately includes adjacent at-risk portions of the involved vertebra (the anatomic compartments the tumor can occult-spread into), not just the gross tumor, while carving away the cord. The spinal cord (or thecal sac) is contoured as an avoidance structure with a planning-organ-at-risk margin (cord PRV), and image guidance at treatment uses bony/vertebral tracking with 6-degree-of-freedom correction. The specific cord dose limits and the toxicity profile (vertebral compression fracture, pain flare, the rare but feared radiation myelopathy) are detailed on the clinical page.

Frameworks used to select spine SBRT (used together, not in isolation).
Framework	Assesses	Implication
NOMS	Neurologic, Oncologic, Mechanical, Systemic	Integrates all axes → SBRT vs surgery vs cEBRT vs combined
ESCC (Bilsky)	Degree of epidural cord compression (0–3)	High-grade (2–3) plus radioresistant histology → separation surgery before SBRT; high-grade plus radiosensitive histology → conventional EBRT
SINS	Mechanical spinal instability	Unstable → stabilization/surgery; SBRT does not stabilize

Key points

Spine SBRT's main advantage is durable local control (~80–90%), especially for radioresistant histologies and oligometastatic disease, not necessarily faster pain relief.
Selection runs through NOMS (neurologic/oncologic/mechanical/systemic), used with the ESCC compression grade and the SINS instability score.
High-grade epidural compression (ESCC 2–3) generally needs separation surgery before SBRT when the tumor is radioresistant, while radiosensitive histologies can be decompressed with conventional radiotherapy; mechanical instability (SINS) needs stabilization: SBRT does neither.
Workflow: near-rigid immobilization, MRI fusion to define tumor and cord, consensus CTV that includes at-risk vertebral compartments, cord/thecal-sac PRV avoidance, bony-tracking IGRT with 6DOF.
The cord constraint shapes the entire plan; dose, fractionation, and toxicity are on the clinical-practice page.

References

Laufer I, Rubin DG, Lis E, et al. The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist. 2013;18(6):744–751. PubMed
Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine. 2010;35(22):E1221–E1229. PubMed
Bilsky MH, Laufer I, Fourney DR, et al. Reliability analysis of the epidural spinal cord compression (ESCC) scale. J Neurosurg Spine. 2010;13(3):324–328. PubMed
Cox BW, Spratt DE, Lovelock M, et al. International spine radiosurgery consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012;83(5):e597–e605. PubMed
Alcorn S, et al. External beam radiation therapy for palliation of symptomatic bone metastases: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2024. ASTRO

Educational synthesis for neurosurgery and radiation-oncology trainees; not a treatment directive. NOMS, SINS, ESCC, and contouring references verified against PubMed during review.